Product Information
FLEQSUVY 25 MG/5 ML SUSPENSION is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $5.9815 per ML under NDC 52652600101. Its NADAC has been published 163 times since Aug 23, 2023.
FDA first approved this application on Feb 4, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the baclofen market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 mg/mL
Manufacturer
Azurity Pharmaceuticals Inc.NDC
52652600101
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BACLOFENApproval Type
New Drug (NDA)
FDA Application
NDA215602FDA Approved
2/4/2022
TE Code
AB
On Market Since
2/7/2022
Pharmacological Classes
Price Statistics
The NADAC for FLEQSUVY 25 MG/5 ML SUSPENSION has been published 163 times since Aug 23, 2023, and over the history we have for it it has risen 4.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.9815 per ML |
|---|---|
| All-time high | $5.9815 (Sep 30, 2026) |
| All-time low | $5.7385 (May 22, 2024) |
| 52-week high | $5.9815 |
| 52-week low | $5.7623 |
| Median price | $5.7683 |
| Average price | $5.8078 |
| Largest weekly change | +3.0% (Dec 31, 2025) |
| Weeks tracked | 163 |
| Tracking since | Aug 23, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 37% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
baclofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
gamma-Aminobutyric Acid-ergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FLEQSUVY 25 MG/5 ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for FLEQSUVY 25 MG/5 ML SUSPENSION, manufactured by Azurity Pharmaceuticals Inc., is $5.9815 per ML (NDC 52652600101), effective Sep 30, 2026.
How has the price of FLEQSUVY 25 MG/5 ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for FLEQSUVY 25 MG/5 ML SUSPENSION has risen 4.1%. It has been tracked across 163 weekly CMS publications since Aug 23, 2023.
What are the highest and lowest recorded NADAC prices for FLEQSUVY 25 MG/5 ML SUSPENSION?
Since Aug 23, 2023, the NADAC for FLEQSUVY 25 MG/5 ML SUSPENSION has ranged from a low of $5.7385 (May 22, 2024) to a high of $5.9815 (Sep 30, 2026), with a median of $5.7683 per ML.
Are there cheaper alternatives to FLEQSUVY 25 MG/5 ML SUSPENSION?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BACLOFEN 25 MG/5 ML SUSPENSION, is $3.7644 per ML — about 37% below FLEQSUVY 25 MG/5 ML SUSPENSION.
Who manufactures FLEQSUVY 25 MG/5 ML SUSPENSION?
FLEQSUVY 25 MG/5 ML SUSPENSION (NDC 52652600101) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.